Yosipovitch, Gil http://orcid.org/0000-0001-6303-1822
de Bruin-Weller, Marjolein http://orcid.org/0000-0002-1249-6993
Armstrong, April http://orcid.org/0000-0003-0064-8707
Wu, Jashin J. http://orcid.org/0000-0002-1722-1892
Herranz, Pedro http://orcid.org/0000-0002-9840-6628
Thaçi, Diamant http://orcid.org/0000-0001-8513-550X
Delevry, Dimittri http://orcid.org/0000-0002-4058-873X
Bagousse, Gaëlle Bégo-Le
Zhang, Raymond http://orcid.org/0000-0002-7778-5083
Shumel, Brad http://orcid.org/0000-0002-9285-8164
Rossi, Ana B. http://orcid.org/0000-0001-5345-678X
Chao, Jingdong
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
https://doi.org/10.1007/s13555-021-00630-9
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
https://doi.org/10.1007/s13555-021-00643-4
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s40257-022-00685-0
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
Received: 16 September 2021
Accepted: 4 October 2021
First Online: 29 October 2021